

Alessandro Gronchi

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4647233/publications.pdf](https://exaly.com/author-pdf/4647233/publications.pdf)

Version: 2025-02-01

418
papers

26,714
citations

2278

93
h-index

6586

147
g-index

508
all docs

508
docs citations

508
times ranked

15871
citing authors

#	ARTICLE	IF	CITATIONS
1	Pleomorphic Liposarcoma of the Extremity and Trunk: Multimodality Therapy for Some but Not All?. Journal of Surgical Oncology, 2025, 131, 291-297.	1.7	0
2	Sarcoma: Last Year's Practice Changing Papers. Annals of Surgical Oncology, 2025, 32, 1497-1503.	1.7	0
3	Is motherhood still possible after pelvic carbon ion radiotherapy? A promising combined fertility-preservation approach. Tumori, 2024, 110, 132-138.	1.5	2
4	Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG). Journal of Clinical Oncology, 2024, 42, 898-906.	17.1	12
5	Initial local resection versus early referral for spermatic cord sarcoma: Any impact on treatment timelines and oncological outcomes?. European Journal of Surgical Oncology, 2024, 50, 108269.	0.9	1
6	Reply to B. Schulte et al. Journal of Clinical Oncology, 2024, 42, 2489-2490.	17.1	0
7	Outcomes of chemotherapy/chemoradiation vs. R2 surgical debulking vs. palliative care in nonresectable locally recurrent rectal cancer. Tumori, 2024, 110, 360-365.	1.5	0
8	Survival after resection of malignant peripheral nerve sheath tumors: Introducing and validating a novel type-specific prognostic model. Neuro-Oncology Advances, 2024, 6, .	0.7	0
9	Primary pelvic soft tissue sarcomas (PELVISARC): outcomes from the TransAtlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). British Journal of Surgery, 2024, 111, .	0.4	2
10	Progress in histology specific treatments in soft tissue sarcoma. Expert Review of Anticancer Therapy, 2024, 24, 845-868.	2.6	1
11	Extent of macroscopic vascular invasion predicts distant metastasis in primary leiomyosarcoma of the inferior vena cava. Journal of Surgical Oncology, 2024, 130, 1691-1699.	1.7	1
12	Histology-Tailored Approach to Soft Tissue Sarcoma. Annals of Surgical Oncology, 2024, 31, 7915-7929.	1.7	2
13	Preoperative nutritional support to tackle morbidity in multivisceral resection for retroperitoneal sarcoma. Early outcomes from a novel nutritional prehabilitation program in a prospective cohort. European Journal of Surgical Oncology, 2024, 50, 108663.	0.9	1
14	Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group. ESMO Open, 2024, 9, 103689.	5.6	0
15	GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression. Clinical Cancer Research, 2024, 30, 5122-5137.	6.4	0
16	How to treat liposarcomas located in retroperitoneum. European Journal of Surgical Oncology, 2023, 49, 1068-1080.	0.9	6
17	Histology-tailored multidisciplinary management of primary retroperitoneal sarcomas. European Journal of Surgical Oncology, 2023, 49, 1061-1067.	0.9	16
18	<sc>CINSARC</sc> in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the <sc>ISG–</sc>1001 study. Cancer Medicine, 2023, 12, 1350-1357.	2.8	17

#	ARTICLE	IF	CITATIONS
19	Quality of Sarcoma Care: Longitudinal Real-Time Assessment and Evidence Analytics of Quality Indicators. <i>Cancers</i> , 2023, 15, 47.	4.0	12
20	Preoperative Neutrophil-to-Lymphocyte Ratio and a New Inflammatory Biomarkers Prognostic Index for Primary Retroperitoneal Sarcomas: Retrospective Monocentric Study. <i>Clinical Cancer Research</i> , 2023, 29, 614-620.	6.4	18
21	Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer. <i>European Journal of Cancer</i> , 2023, 186, 52-61.	3.3	45
22	Long term outcome of complex surgical resection and reconstruction for rare thoracic cancers. <i>Tumori</i> , 2023, 109, 450-457.	1.5	2
23	NIRO or No-go? Positioning a Novel Systemic Treatment Option for Desmoid Tumours. <i>Annals of Surgical Oncology</i> , 2023, 30, 2570-2573.	1.7	1
24	Staging Systems and Nomograms for Soft Tissue Sarcoma. <i>Current Oncology</i> , 2023, 30, 3648-3671.	3.2	12
25	Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft. <i>DMM Disease Models and Mechanisms</i> , 2023, 16, .	2.7	7
26	Data Dissemination of the Role of Neoadjuvant Radiation in Retroperitoneal Sarcoma: A CTOS and CSSO Survey. <i>Current Oncology</i> , 2023, 30, 5807-5815.	3.2	0
27	Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study. <i>European Journal of Cancer</i> , 2023, 190, 112949.	3.3	4
28	A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2). <i>Annals of Surgical Oncology</i> , 2023, 30, 4573-4575.	1.7	11
29	Desmoid tumours (extra-abdominal), a surgeon's nightmare. <i>Bone and Joint Journal</i> , 2023, 105-B, 729-734.	3.8	1
30	Corrigenda. <i>Bone and Joint Journal</i> , 2023, 105-B, 1030-1030.	3.8	0
31	Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study. <i>European Journal of Cancer</i> , 2023, 195, 113391.	3.3	6
32	Postnephrectomy outcomes following <i>en bloc</i> resection of primary retroperitoneal sarcoma: multicentre study. <i>British Journal of Surgery</i> , 2022, 109, 165-168.	0.4	5
33	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG–STS 1001 randomized trial. <i>Cancer</i> , 2022, 128, 85-93.	4.4	66
34	Diagnosis strategy of adipocytic soft-tissue tumors in adults: a consensus from European experts. <i>European Journal of Surgical Oncology</i> , 2022, 48, 518-525.	0.9	16
35	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	6.4	25
36	SELNET clinical practice guidelines for soft tissue sarcoma and GIST. <i>Cancer Treatment Reviews</i> , 2022, 102, 102312.	10.1	50

#	ARTICLE	IF	CITATIONS
37	Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall: Outcome Improvement Over Time at a Single Institution. <i>Annals of Surgical Oncology</i> , 2022, 29, 3274-3286.	1.7	6
38	ASO Author Reflections: Outcome Improvement Over Time in Extremity and Trunk Wall Soft Tissue Sarcomas: To Whom the Merit?. <i>Annals of Surgical Oncology</i> , 2022, , .	1.7	1
39	Treatment strategies and outcomes of primary Myxofibrosarcomas in a large patients cohort. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1723-1729.	0.9	14
40	So Now What? Unanswered Questions Regarding Retroperitoneal Sarcomas, Hospital Volume, Multidisciplinary Expertise, and Outcomes. <i>Annals of Surgical Oncology</i> , 2022, , .	1.7	1
41	Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 2304-2314.	1.7	5
42	A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis. <i>Clinical Cancer Research</i> , 2022, 28, 4027-4032.	6.4	34
43	Sarcuator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 4376-4385.	1.7	24
44	Residual Adrenal Function After Multivisceral Resection With Adrenalectomy in Adult Patients. <i>JAMA Surgery</i> , 2022, 157, 415.	9.8	5
45	Risk of misclassification during diagnosis of malnutrition in retroperitoneal sarcoma patients. <i>Clinical Nutrition ESPEN</i> , 2022, 49, 459-465.	0.8	4
46	Overall survival in abdominal wall sarcoma treated with curative intent surgery: A retrospective study from two European referral centres. <i>Journal of Surgical Oncology</i> , 2022, , .	1.7	1
47	Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomas—Looking Forward. <i>Cancers</i> , 2022, 14, 1831.	4.0	12
48	The evolution of adjuvant/neoadjuvant trials for resectable localized sarcoma. <i>Journal of Surgical Oncology</i> , 2022, 125, 17-27.	1.7	6
49	Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 491-503.	2.6	9
50	SELNET clinical practice guidelines for bone sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103685.	5.3	21
51	Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States. <i>Hpb</i> , 2022, 24, 1688-1696.	0.3	12
52	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092â€”2092 STRASS trial. <i>Cancer</i> , 2022, 128, 2796-2805.	4.4	22
53	Firstâ€”line chemotherapy in advanced intraâ€”abdominal wellâ€”differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. <i>Cancer</i> , 2022, 128, 2932-2938.	4.4	3
54	WHO Pathology. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 321-340.	1.9	9

#	ARTICLE	IF	CITATIONS
55	Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma. <i>Cancers</i> , 2022, 14, 2624.	4.0	2
56	Desmoid Tumors. , 2022, , 619-627.		2
57	Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. <i>European Journal of Cancer</i> , 2022, 171, 183-192.	3.3	9
58	Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2022, 29, 7335-7348.	1.7	22
59	First and further-line multidisciplinary treatment of retroperitoneal sarcomas. <i>Current Opinion in Oncology</i> , 2022, 34, 328-334.	2.3	2
60	Traditional risk scores do not properly predict perioperative morbidity and mortality for retroperitoneal sarcoma resection. <i>Journal of Surgical Oncology</i> , 2022, 126, 1367-1368.	1.7	1
61	Contemporary role of amputation for patients with extremity soft tissue sarcoma. <i>European Journal of Surgical Oncology</i> , 2022, , .	0.9	3
62	Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: A guide for surgical oncologists. <i>Journal of Surgical Oncology</i> , 2021, 123, 12-23.	1.7	7
63	Management of meningeal solitary fibrous tumors/hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy?. <i>Acta Oncologica</i> , 2021, 60, 35-41.	1.9	17
64	Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2021, 127, 729-738.	4.4	35
65	The Prognostic Role of β -Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only. <i>Annals of Surgery</i> , 2021, 273, 1094-1101.	4.9	31
66	ASO Author Reflections: Reexcision after Macroscopically Complete Unplanned Excision in Extremity and Trunk Wall Soft Tissue Sarcoma: Is Less More?. <i>Annals of Surgical Oncology</i> , 2021, 28, 4718-4719.	1.7	1
67	Unplanned Excision of Extremity and Trunk Wall Soft Tissue Sarcoma: To Re-resect or Not to Re-resect?. <i>Annals of Surgical Oncology</i> , 2021, 28, 4706-4717.	1.7	19
68	Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, .	11.5	15
69	Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 6882-6889.	1.7	15
70	Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin. <i>Cancers</i> , 2021, 13, 1453.	4.0	16
71	Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program. <i>Current Opinion in Oncology</i> , 2021, 33, 301-308.	2.3	15
72	Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 7854-7863.	1.7	19

#	ARTICLE	IF	CITATIONS
73	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	4.4	129
74	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 7873-7888.	1.7	145
75	ASO Author Reflections: Selecting Patients for Recurrent Retroperitoneal Sarcoma Surgery: The Challenging Trade-Off Between Oncologic Outcome and Morbidity. <i>Annals of Surgical Oncology</i> , 2021, , .	1.7	1
76	Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis. <i>Cancer Medicine</i> , 2021, 10, 4356-4365.	2.8	5
77	Management of serious complications in intra-abdominal desmoid-type fibromatosis. <i>Cancer Reports</i> , 2021, 4, .	1.9	7
78	De-differentiation within well-differentiated liposarcoma of the extremity or trunk: Implications for clinical management. <i>Journal of Surgical Oncology</i> , 2021, 124, 838-845.	1.7	6
79	Oncological outcomes after major vascular resections for primary retroperitoneal liposarcoma. <i>European Journal of Surgical Oncology</i> , 2021, 47, 3004-3010.	0.9	16
80	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2173-2181.	0.9	5
81	Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2166-2172.	0.9	37
82	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STs 1001 Randomized Phase III Trial. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2539-2552.	1.7	4
83	Major vascular resection in retroperitoneal sarcoma surgery. <i>Surgery</i> , 2021, 170, 848-856.	1.9	16
84	Recurrent neck myxofibrosarcoma: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, .	0.9	1
85	Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms. <i>European Journal of Cancer</i> , 2021, 157, 291-300.	3.3	15
86	Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 2705-2714.	1.7	27
87	Primary mesenteric sarcomas: Collaborative experience from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Journal of Surgical Oncology</i> , 2021, 123, 1057-1066.	1.7	3
88	Gastrointestinal Stromal Tumors (GISTs). <i>UNIPA Springer Series</i> , 2021, , 1021-1059.	0.0	0
89	Volume-Outcome Relationship in Surgery of Soft Tissue Sarcomas. <i>Updates in Surgery Series</i> , 2021, , 67-84.	0.0	0
90	Individualizing Follow-Up Strategies in High-Grade Soft Tissue Sarcoma with Flexible Parametric Competing Risk Regression Models. <i>Cancers</i> , 2020, 12, 47.	4.0	17

#	ARTICLE	IF	CITATIONS
91	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. <i>Oncologist</i> , 2020, 25, e1562-e1573.	3.6	6
92	Desmoid tumors: To treat or not to treat, That is the question. <i>Cancer</i> , 2020, 126, 5213-5221.	4.4	42
93	Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Società Italiana di Ginecologia e Obstetrica). <i>Journal of Obstetrics and Gynaecology</i> , 2020, 46, 100-105.	3.3	26
94	Extraskelletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management. <i>Cancers</i> , 2020, 12, 2703.	4.0	33
95	Head and neck adult-type soft tissues sarcomas: survival analysis and comparison between the last two editions of the TNM staging system. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 278, 3003-3010.	1.7	3
96	The Landmark Series: Multimodality Treatment of Extremity Sarcoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3672-3682.	1.7	9
97	Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG. <i>Cancer</i> , 2020, 126, 4917-4925.	4.4	22
98	Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals. <i>Cancer</i> , 2020, 126, 4615-4616.	4.4	0
99	Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 1366-1377.	21.9	319
100	ASO Author Reflections: Moving the Needle in Extremity and Trunk Soft Tissue Sarcoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 899-900.	1.7	1
101	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISC), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020, 38, 2178-2186.	17.1	170
102	Improved Biopsy Accuracy in Retroperitoneal Dedifferentiated Liposarcoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 4574-4581.	1.7	11
103	Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 571-576.	2.9	8
104	Defining Which Patients Are at High Risk for Recurrence of Soft Tissue Sarcoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, .	4.3	13
105	Liver resection for sarcoma metastases: A systematic review and experience from two European centres. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1807-1813.	0.9	10
106	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020, 5, e000604.	5.6	13
107	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. <i>JAMA Surgery</i> , 2020, 155, e200397.	9.8	37
108	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	4.4	104

#	ARTICLE	IF	CITATIONS
109	Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 5534-5538.	6.4	20
110	Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas. <i>JAMA Oncology</i> , 2020, 6, 535.	13.6	33
111	A sommelier to guide wine selection and a specialist to manage the sarcoma patient: Barriers to referral and definition of a sarcoma specialist. <i>Journal of Surgical Oncology</i> , 2020, 121, 925-926.	1.7	4
112	The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1320-1326.	0.9	21
113	Extrameningeal solitary fibrous tumors—surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet. <i>Cancer</i> , 2020, 126, 3002-3012.	4.4	49
114	Soft-tissue sarcoma in adults: An update on the current state of histotype-specific management in an era of personalized medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 200-229.	169.1	346
115	Inoperable Primary Retroperitoneal Sarcomas: Clinical Characteristics and Reasons Against Resection at a Single Referral Institution. <i>Annals of Surgical Oncology</i> , 2020, 28, 1151-1157.	1.7	16
116	Extraskeletal Myxoid Chondrosarcoma with Molecularly Confirmed Diagnosis: A Multicenter Retrospective Study Within the Italian Sarcoma Group. <i>Annals of Surgical Oncology</i> , 2020, 28, 1142-1150.	1.7	25
117	A Prospective Observational Study of Multivisceral Resection for Retroperitoneal Sarcoma: Clinical and Patient-Reported Outcomes 1 Year After Surgery. <i>Annals of Surgical Oncology</i> , 2020, 28, 3904-3916.	1.7	15
118	Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 Years. <i>Annals of Surgical Oncology</i> , 2020, 28, 1700-1709.	1.7	40
119	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 96-107.	3.3	308
120	ASO Author Reflections: Understanding the Impact of Primary Retroperitoneal Sarcoma Resection on Patient Well-being: One Step Forward in Learning How Caring for Patients is as Important as Curing Their Cancers. <i>Annals of Surgical Oncology</i> , 2020, , .	1.7	1
121	Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients—A propensity score analysis. <i>Journal of Surgical Oncology</i> , 2019, 119, 318-323.	1.7	10
122	Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin. <i>British Journal of Cancer</i> , 2019, 121, 464-473.	5.7	11
123	Intraperitoneal Invasion of Retroperitoneal Sarcomas: A Risk Factor for Dismal Prognosis. <i>Annals of Surgical Oncology</i> , 2019, 26, 3535-3541.	1.7	10
124	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2—3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 1148-1159.	21.9	343
125	Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft. <i>Cancers</i> , 2019, 11, 1015.	4.0	23
126	ASO Author Reflections: A Breach in the Border—Retroperitoneal Sarcoma with an Intraperitoneal Component. <i>Annals of Surgical Oncology</i> , 2019, 26, 838-839.	1.7	0

#	ARTICLE	IF	CITATIONS
127	The evolving role of patient advocates in rare cancers: opportunities and challenges. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 1-3.	1.6	2
128	Treatment of Desmoid Tumors in 2019. <i>JAMA Oncology</i> , 2019, 5, 567.	13.6	38
129	The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. <i>European Journal of Cancer</i> , 2019, 109, 51-60.	3.3	150
130	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). <i>Clinical Cancer Research</i> , 2019, 25, 5295-5300.	6.4	84
131	Personalizing surgical margins in retroperitoneal sarcomas: an update. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 613-631.	2.6	49
132	Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1503-1515.	2.3	16
133	Trabectedin and Radiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. <i>EClinicalMedicine</i> , 2019, 9, 35-43.	8.8	54
134	NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas. <i>Journal of Pathology</i> , 2019, 249, 90-101.	5.2	28
135	Outcome of ilio caval resection and reconstruction for retroperitoneal sarcoma. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2019, 7, 547-556.	1.8	24
136	Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. <i>Clinical Cancer Research</i> , 2019, 25, 2664-2671.	6.4	83
137	Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. <i>Oncologist</i> , 2019, 24, e536-e541.	3.6	27
138	Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. <i>EClinicalMedicine</i> , 2019, 17, 100215.	8.8	52
139	New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR: making progress through collaboration. <i>Current Opinion in Oncology</i> , 2019, 31, 310-316.	2.3	57
140	Combination of PPAR α Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas. <i>Clinical Cancer Research</i> , 2019, 25, 7565-7575.	6.4	17
141	Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. <i>European Journal of Cancer</i> , 2019, 106, 225-233.	3.3	32
142	Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2019, 125, 1290-1300.	4.4	75
143	Baseline and Postoperative C-reactive Protein Levels Predict Long-Term Survival After Lung Metastasectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 869-875.	1.7	12
144	Treatment challenges in and outside a network setting: Soft tissue sarcomas. <i>European Journal of Surgical Oncology</i> , 2019, 45, 31-39.	0.9	29

#	ARTICLE	IF	CITATIONS
145	Malnutrition and Perioperative Nutritional Support in Retroperitoneal Sarcoma Patients: Results from a Prospective Study. <i>Annals of Surgical Oncology</i> , 2019, 27, 2025-2032.	1.7	23
146	Staging systems and nomograms in soft tissue sarcoma: outcome prediction by categorization or personalization?. <i>Chinese Clinical Oncology</i> , 2019, 8, S12-S12.	1.4	6
147	Towards a Global Collaboration: the Trans-Atlantic Retroperitoneal Sarcoma Working Group. <i>Updates in Surgery Series</i> , 2019, , 173-178.	0.0	0
148	History of Surgery in Retroperitoneal Sarcomas. <i>Updates in Surgery Series</i> , 2019, , 1-7.	0.0	1
149	Predicting the Risk of Recurrence in Retroperitoneal Sarcoma. <i>Updates in Surgery Series</i> , 2019, , 143-153.	0.0	0
150	High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 93, 28-36.	3.3	56
151	Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre: Should Radiotherapy Still be a Standard?. <i>Annals of Surgical Oncology</i> , 2018, 25, 1536-1543.	1.7	25
152	Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma. <i>JAMA Oncology</i> , 2018, 4, 483.	13.6	247
153	Botulinum toxin type A affects the transcriptome of cell cultures derived from muscle biopsies of controls and spastic patients. <i>Toxicology in Vitro</i> , 2018, 50, 124-136.	2.7	2
154	Prospective assessment of the predictive value of the <i>BRCA1</i> gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial. <i>Cancer Medicine</i> , 2018, 7, 1575-1577.	2.8	7
155	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone – Multicenter analysis outside clinical trial. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1384-1390.	0.9	86
156	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	13.6	63
157	Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. <i>Oncologist</i> , 2018, 23, 1250-1259.	3.6	25
158	Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. <i>European Journal of Surgical Oncology</i> , 2018, 44, 810-815.	0.9	30
159	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC – STBSG). <i>International Journal of Cancer</i> , 2018, 142, 2610-2620.	4.5	34
160	Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. <i>European Journal of Surgical Oncology</i> , 2018, 44, 571-579.	0.9	50
161	Synovial sarcomas of the upper aero-digestive tract: is there a role for conservative surgery?. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2018, 26, 94-101.	1.8	3
162	Working to improve the management of sarcoma patients across Europe: a policy checklist. <i>BMC Cancer</i> , 2018, 18, .	3.0	20

#	ARTICLE	IF	CITATIONS
163	Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study. <i>European Journal of Cancer</i> , 2018, 94, 187-198.	3.3	6
164	European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy. <i>Clinical Oncology</i> , 2018, 30, 448-454.	1.6	29
165	Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. <i>Acta Oncologica</i> , 2018, 57, 1117-1126.	1.9	11
166	Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma. <i>Annals of Surgery</i> , 2018, 267, 959-964.	4.9	155
167	Radiomic analysis of soft tissues sarcomas can distinguish intermediate from high-grade lesions. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 829-840.	3.7	110
168	Retroperitoneal sarcomas: Big tumors that involve more than just "Getting it Out". <i>Journal of Surgical Oncology</i> , 2018, 117, 5-6.	1.7	2
169	Soft Tissue Tumors of the Groin and Inguinal Region. , 2018, , 123-157.		1
170	Historical perspectives and future directions in the surgical management of retroperitoneal sarcoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 7-11.	1.7	21
171	Perioperative Management of Extremity Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 118-124.	17.1	37
172	Consistent Margin-Status Reporting in Soft Tissue Sarcoma Is Essential to Establish Risk-Adapted Strategies Integrating Biology and Histotype in Perioperative Treatments. <i>Journal of Clinical Oncology</i> , 2018, 36, 2357-2358.	17.1	5
173	ASO Author Reflections: Evolving Concepts for Radiation Therapy in Extremity and Trunk Soft Tissue Sarcoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 942-943.	1.7	1
174	A call to action: Why sarcoma surgery needs to be centralized. <i>Cancer</i> , 2018, 124, 4452-4454.	4.4	14
175	Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. <i>European Journal of Cancer</i> , 2018, 105, 19-27.	3.3	63
176	Radiation-Induced Sarcoma of the Head and Neck: A Review of the Literature. <i>Frontiers in Oncology</i> , 2018, 8, .	2.7	41
177	Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study. <i>Cancer</i> , 2018, 124, 4056-4063.	4.4	45
178	Surgical resection as an adjuvant to tyrosine kinase inhibitors in metastatic GIST: Association or causation?/Are we any closer to an answer?. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1287-1288.	0.9	1
179	Minimally Invasive Surgery for Retroperitoneal Sarcoma: Just Because We Can Does Not Mean We Should. <i>Annals of Surgical Oncology</i> , 2018, 25, 2129-2131.	1.7	6
180	Unsupervised versus Supervised Identification of Prognostic Factors in Patients with Localized Retroperitoneal Sarcoma: A Data Clustering and Mahalanobis Distance Approach. <i>BioMed Research International</i> , 2018, 2018, 1-11.	2.7	12

#	ARTICLE	IF	CITATIONS
181	Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1855.	4.5	5
182	2018 ESMO Sarcoma and GIST Symposium: "take-home messages"™ in soft tissue sarcoma. <i>ESMO Open</i> , 2018, 3, e000390.	3.6	5
183	Towards the standard use of (neo)adjuvant chemotherapy in selected localised soft tissue sarcoma at high risk of relapse: are we finally getting there?. <i>European Journal of Cancer</i> , 2018, 101, 251-253.	3.3	2
184	The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk. <i>JAMA Oncology</i> , 2018, 4, 1167.	13.6	10
185	Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma. <i>Anticancer Research</i> , 2018, 38, 3535-3542.	1.2	14
186	Novel intra-genic large deletions of <i>CTNNB1</i> gene identified in WT desmoid-type fibromatosis. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 495-503.	3.5	17
187	Principles of Local Therapy of Soft Tissue Neoplasms. , 2018, , 55-65.		0
188	Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis. <i>Oncotarget</i> , 2018, 9, 18607-18626.	1.7	13
189	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 34617-34627.	1.7	8
190	Surgical management of retroperitoneal sarcoma and opportunities for global collaboration. <i>Chinese Clinical Oncology</i> , 2018, 7, 39-39.	1.4	24
191	Staging, nomograms and other predictive tools in retroperitoneal soft tissue sarcoma. <i>Chinese Clinical Oncology</i> , 2018, 7, 36-36.	1.4	17
192	Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome. <i>Clinical Cancer Research</i> , 2017, 23, 273-282.	6.4	68
193	Genome-Wide Analysis Identifies <i>MEN1</i> and <i>MAX</i> Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. <i>Molecular Cancer Research</i> , 2017, 15, 553-562.	2.9	52
194	Pharmacological therapies for Liposarcoma. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 361-377.	2.9	17
195	Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Transatlantic RPS Working Group. <i>Cancer</i> , 2017, 123, 1971-1978.	4.4	114
196	Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. <i>British Journal of Surgery</i> , 2017, 104, 347-357.	0.4	84
197	Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. <i>European Journal of Cancer</i> , 2017, 76, 84-92.	3.3	25
198	Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients. <i>European Journal of Cancer</i> , 2017, 74, 9-16.	3.3	66

#	ARTICLE	IF	CITATIONS
199	Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. <i>Acta Oncologica</i> , 2017, 56, 1013-1020.	1.9	35
200	Soft tissue sarcoma nomograms and their incorporation into practice. <i>Cancer</i> , 2017, 123, 2802-2820.	4.4	113
201	Neoadjuvant treatment: a novel standard?. <i>Current Opinion in Oncology</i> , 2017, 29, 253-259.	2.3	10
202	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology</i> , The, 2017, 18, 812-822.	21.9	381
203	β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. <i>Molecular Oncology</i> , 2017, 11, 1495-1507.	4.2	27
204	Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 86-91.	1.9	73
205	Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 415-429.	3.8	105
206	HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 582-586.	3.5	38
207	An Update on Non-extremity Soft Tissue Sarcomas. <i>Clinical Oncology</i> , 2017, 29, 516-527.	1.6	6
208	Renal angiomyolipomas: At least two diseases. A series of patients treated at two European institutions. <i>European Journal of Surgical Oncology</i> , 2017, 43, 831-836.	0.9	11
209	Surgery for recurrence in retroperitoneal leiomyosarcoma: Is it all about selection?. <i>Journal of Surgical Oncology</i> , 2017, 116, 267-268.	1.7	2
210	Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. <i>British Journal of Cancer</i> , 2017, 117, 340-346.	5.7	21
211	Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. <i>BMC Medicine</i> , 2017, 15, .	7.4	60
212	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. <i>Acta Oncologica</i> , 2017, 56, 88-92.	1.9	154
213	(Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair. <i>European Journal of Cancer</i> , 2017, 70, 1-11.	3.3	39
214	Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. <i>Journal of Investigative Dermatology</i> , 2017, 137, 484-493.	0.7	28
215	High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. <i>Sarcoma</i> , 2017, 2017, 1-5.	1.5	6
216	Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting. <i>BMC Medicine</i> , 2017, 15, .	7.4	4

#	ARTICLE	IF	CITATIONS
217	Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. <i>Clinical Sarcoma Research</i> , 2017, 7, .	2.0	22
218	Long-Term Results of Thoraco-Pleuro-Pneumonectomy (TPP) for Recurrent Thoracic Sarcomas. <i>Annals of Surgical Oncology</i> , 2017, 24, 551-554.	1.7	2
219	Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. <i>Oncotarget</i> , 2017, 8, 60036-60045.	1.7	14
220	Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. <i>Journal of Clinical Oncology</i> , 2017, 35, 1713-1720.	17.1	153
221	Adjacent, Adherent, Invaded: A Spectrum of Biologic Aggressiveness Rather Than a Rationale for Selecting Organ Resection in Primary Retroperitoneal Sarcomas. <i>Annals of Surgical Oncology</i> , 2017, 25, 13-16.	1.7	14
222	Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs. <i>Modern Pathology</i> , 2017, 31, 160-168.	5.0	5
223	External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2017, 25, 754-767.	1.7	98
224	Sarcoma nomograms: a light over the darkness. <i>Oncoscience</i> , 2017, 4, 15-16.	1.6	8
225	Retroperitoneal Sarcoma Involving the Inferior Vena Cava. , 2017, , 61-74.		1
226	Local Ablative Therapies to Metastatic Soft Tissue Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, , e566-e575.	5.1	17
227	Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS). <i>Annals of Surgery</i> , 2016, 263, 1002-1009.	4.9	416
228	Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. <i>Spine</i> , 2016, 41, 1049-1057.	2.4	72
229	External validation of a multi-institutional retroperitoneal sarcoma nomogram. <i>Cancer</i> , 2016, 122, 1417-1424.	4.4	85
230	Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 671-680.	21.9	351
231	Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSC) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. <i>Gynecologic Oncology</i> , 2016, 142, 95-101.	1.6	13
232	The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 473-484.	2.6	5
233	Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss. <i>Molecular Cancer Research</i> , 2016, 14, 820-829.	2.9	25
234	Desmoid-Type Fibromatosis. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 803-826.	1.9	64

#	ARTICLE	IF	CITATIONS
235	<i>AKT1</i> and <i>BRAF</i> mutations in pediatric aggressive fibromatosis. <i>Cancer Medicine</i> , 2016, 5, 1204-1213.	2.8	28
236	Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma – An analysis of the EORTC 62012 study of the EORTC STBSG. <i>European Journal of Cancer</i> , 2016, 64, 44-51.	3.3	33
237	Cancer registries and randomised clinical trials in rare tumours: At the two extremes of daily clinical practice. <i>European Journal of Cancer</i> , 2016, 64, 113-115.	3.3	5
238	The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG): “Red wine or white?”. <i>Annals of Surgical Oncology</i> , 2016, 23, 4418-4420.	1.7	14
239	Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. <i>Annals of Surgical Oncology</i> , 2016, 23, 2735-2744.	1.7	57
240	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Annals of Oncology</i> , 2016, 27, 2283-2288.	1.5	95
241	The Italian Society of Surgical Oncology (SICO) survey on the minimum requirements of rare cancers referral centers. <i>Updates in Surgery</i> , 2016, 68, 321-323.	1.8	2
242	Indications for surgery in advanced/metastatic GIST. <i>European Journal of Cancer</i> , 2016, 63, 154-167.	3.3	42
243	Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. <i>Surgical Oncology</i> , 2016, 25, 125-131.	2.1	40
244	Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC –) Tj ETQq0 0 0 rgBT /Overlock emphasis on magnetic resonance imaging. <i>European Journal of Cancer</i> , 2016, 56, 37-44.	3.3	45
245	Morcellator's Port-site Metastasis of a Uterine Smooth Muscle Tumor of Uncertain Malignant Potential After Minimally Invasive Myomectomy. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 647-649.	0.6	14
246	Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1071-1083.	0.9	59
247	Resectable extra-pleural and extra-meningeal solitary fibrous tumours: A multi-centre prognostic study. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1064-1070.	0.9	91
248	Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. <i>European Journal of Cancer</i> , 2016, 58, 62-72.	3.3	120
249	Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC – STBSG) recommendations for pathological examination and reporting. <i>European Journal of Cancer</i> , 2016, 53, 84-95.	3.3	111
250	Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). <i>Clinical Cancer Research</i> , 2016, 22, 837-846.	6.4	75
251	Are We Allowed to Limit Surgical Aggressiveness With Small Rectal Gastrointestinal Stromal Tumors?. <i>Annals of Surgical Oncology</i> , 2016, 24, 1153-1156.	1.7	4
252	Accreditation for centers of sarcoma surgery. <i>Updates in Surgery</i> , 2016, 69, 1-7.	1.8	16

#	ARTICLE	IF	CITATIONS
253	Abdominosacral resection for locally recurring rectal cancer. <i>World Journal of Gastrointestinal Surgery</i> , 2016, 8, 770.	1.5	4
254	Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. <i>British Journal of Surgery</i> , 2015, 102, 1079-1087.	0.4	45
255	KIT, PDGFRA, and BRAF Mutational Spectrum Impacts on the Natural History of Imatinib-naive Localized GIST. <i>American Journal of Surgical Pathology</i> , 2015, 39, 922-930.	3.9	62
256	Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 383-393.	3.9	106
257	Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. <i>Modern Pathology</i> , 2015, 28, 1074-1083.	5.0	70
258	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 4276-4283.	17.1	146
259	Personalizing surgical margins in retroperitoneal sarcomas. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 553-567.	2.6	35
260	Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients. <i>European Journal of Cancer</i> , 2015, 51, 186-192.	3.3	129
261	Mesenchymal chondrosarcoma: Prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. <i>European Journal of Cancer</i> , 2015, 51, 374-381.	3.3	139
262	The role of hyperthermic intraperitoneal chemotherapy (HIPEC) and isolated perfusion (ILP) interventions in sarcoma. <i>Journal of Surgical Oncology</i> , 2015, 111, 570-579.	1.7	10
263	Management of sporadic desmoid-type fibromatosis: A European consensus approach based on patients' and professionals' expertise. A Sarcoma Patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. <i>European Journal of Cancer</i> , 2015, 51, 127-136.	3.3	190
264	Individualizing the use/non-use of radiation therapy (RT) in soft tissue sarcoma (STS): When abstention is better than care. <i>Journal of Surgical Oncology</i> , 2015, 111, 133-134.	1.7	8
265	Collaborations Between SSO and the Connective Tissue Oncology Society (CTOS) Series. <i>Annals of Surgical Oncology</i> , 2015, 22, 2815-2816.	1.7	1
266	Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. <i>Journal of Clinical Oncology</i> , 2015, 33, 3628-3634.	17.1	61
267	Imatinib in advanced chordoma: A retrospective case series analysis. <i>European Journal of Cancer</i> , 2015, 51, 2609-2614.	3.3	79
268	Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. <i>European Journal of Cancer</i> , 2015, 51, 2800-2807.	3.3	59
269	Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. <i>European Journal of Cancer</i> , 2015, 51, 210-217.	3.3	102
270	Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis. <i>British Journal of Surgery</i> , 2014, 101, 1674-1680.	0.4	32

#	ARTICLE	IF	CITATIONS
271	Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. <i>British Journal of Cancer</i> , 2014, 111, 1350-1362.	5.7	21
272	Surgical management of localized soft tissue tumors. <i>Cancer</i> , 2014, 120, 2638-2648.	4.4	46
273	Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: Analysis of 291 consecutive patients at a tertiary reference sarcoma center. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1662-1670.	0.9	34
274	Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. <i>Annals of Oncology</i> , 2014, 25, 2425-2432.	1.5	132
275	Emerging therapies for adult soft tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 689-704.	2.6	50
276	Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. <i>Neuro-Oncology</i> , 2014, 16, 72-80.	0.9	12
277	High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. <i>Clinical Sarcoma Research</i> , 2014, 4, .	2.0	43
278	MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 249-259.	1.7	27
279	Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasmâ€”a position paper from the Italian and the French Sarcoma Group. <i>Annals of Oncology</i> , 2014, 25, 578-583.	1.5	146
280	Activity of sunitinib in extraskeletal myxoid chondrosarcoma. <i>European Journal of Cancer</i> , 2014, 50, 1657-1664.	3.3	70
281	Axial skeletal osteosarcoma: a 25-year monoinstitutional experience in children and adolescents. <i>Medical Oncology</i> , 2014, 31, .	2.5	17
282	Thoracopleuropneumonectomy with Riblike Reconstruction for Recurrent Thoracic Sarcomas. <i>Annals of Surgical Oncology</i> , 2014, 21, 1610-1615.	1.7	11
283	Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. <i>European Journal of Cancer</i> , 2014, 50, 3021-3028.	3.3	48
284	Prognostic Factors and Outcome of Spermatic Cord Sarcoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 3557-3563.	1.7	28
285	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. <i>European Journal of Cancer</i> , 2014, 50, 784-792.	3.3	79
286	Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib â€” Analysis of prognostic factors (EORTC-STBSG collaborative study). <i>European Journal of Surgical Oncology</i> , 2014, 40, 412-419.	0.9	132
287	Desmoid-Type Fibromatosis and Pregnancy. <i>Annals of Surgery</i> , 2014, 259, 973-978.	4.9	96
288	Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection. <i>Annals of Surgical Oncology</i> , 2014, 22, 1447-1454.	1.7	152

#	ARTICLE	IF	CITATIONS
289	Identification of a gene expression driven progression pathway in myxoid liposarcoma. <i>Oncotarget</i> , 2014, 5, 5965-5977.	1.7	16
290	Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. <i>Clinical Sarcoma Research</i> , 2013, 3, .	2.0	38
291	Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. <i>Clinical Sarcoma Research</i> , 2013, 3, .	2.0	86
292	Adjuvant Therapy for High-Risk Soft Tissue Sarcoma in the Adult. Current Treatment Options in <i>Oncology</i> , 2013, 14, 415-424.	4.3	12
293	Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience. <i>Annals of Surgical Oncology</i> , 2013, 20, 2937-2943.	1.7	193
294	Risk stratification models and mutational analysis: Keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2013, 49, 884-892.	3.3	24
295	Localised thoracic sarcomas: Outcome improvement over time at a single institution. <i>European Journal of Cancer</i> , 2013, 49, 2689-2697.	3.3	14
296	Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought. <i>Annals of Surgical Oncology</i> , 2013, 20, 4096-4102.	1.7	196
297	Treatment of Localized Sarcomas. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 921-938.	2.4	12
298	Quality of Local Treatment or Biology of the Tumor: Which are the Trump Cards for Loco-regional Control of Retroperitoneal Sarcoma?. <i>Annals of Surgical Oncology</i> , 2013, 20, 2111-2113.	1.7	31
299	Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. <i>Clinical Sarcoma Research</i> , 2013, 3, .	2.0	32
300	In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/differentiated liposarcomas. <i>Laboratory Investigation</i> , 2013, 93, 1232-1240.	3.5	18
301	Response to chemotherapy of solitary fibrous tumour: A retrospective study. <i>European Journal of Cancer</i> , 2013, 49, 2376-2383.	3.3	67
302	Cytoreductive Surgery in Advanced GIST: Timing is Everything. <i>Annals of Surgical Oncology</i> , 2013, 20, 4059-4060.	1.7	7
303	Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. <i>Annals of Oncology</i> , 2013, 24, 817-823.	1.5	68
304	Phase II study on lapatinib in advanced EGFR-positive chordoma. <i>Annals of Oncology</i> , 2013, 24, 1931-1936.	1.5	121
305	Efficacy and Economic Value of Adjuvant Imatinib for Gastrointestinal Stromal Tumors. <i>Oncologist</i> , 2013, 18, 689-696.	3.6	9
306	Outcome Prediction in Primary Resected Retroperitoneal Soft Tissue Sarcoma: Histology-Specific Overall Survival and Disease-Free Survival Nomograms Built on Major Sarcoma Center Data Sets. <i>Journal of Clinical Oncology</i> , 2013, 31, 1649-1655.	17.1	278

#	ARTICLE	IF	CITATIONS
307	CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence. <i>Cancer</i> , 2013, 119, 3696-3702.	4.4	154
308	Mode of action of trabectedin in myxoid liposarcomas. <i>Oncogene</i> , 2013, 33, 5201-5210.	6.6	111
309	A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep) Tj ETQq1 1 0.784314 1.5 BT /Overlock 10	1.5	43
310	Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. <i>Annals of Oncology</i> , 2012, 23, 1067-1073.	1.5	187
311	Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 850-856.	17.1	145
312	Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. <i>Annals of Oncology</i> , 2012, 23, 771-776.	1.5	125
313	Phase II Study of Imatinib in Advanced Chordoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 914-920.	17.1	220
314	Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in management. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1053-1068.	2.6	7
315	Sunitinib malate in solitary fibrous tumor (SFT). <i>Annals of Oncology</i> , 2012, 23, 3171-3179.	1.5	129
316	High-grade Sarcomatous Overgrowth in Solitary Fibrous Tumors. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1202-1215.	3.9	90
317	Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. <i>Neuro-Oncology</i> , 2012, 14, 736-744.	0.9	22
318	Clinical, Pathological and Surgical Characteristics of Duodenal Gastrointestinal Stromal Tumor and Their Influence on Survival: A Multi-Center Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 3361-3367.	1.7	58
319	Surgery in soft tissue sarcoma: more conservative in extremities, more extended in the retroperitoneum. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1079-1087.	2.6	18
320	Technical Considerations in Surgery for Retroperitoneal Sarcomas: Position Paper from E-Surge, a Master Class in Sarcoma Surgery, and EORTCâ€“STBSG. <i>Annals of Surgical Oncology</i> , 2012, 19, 2981-2991.	1.7	208
321	Optimal Approach to Sporadic Desmoid Tumors: From Radical Surgery to Observation. Time for a Consensus?. <i>Annals of Surgical Oncology</i> , 2012, 19, 3995-3997.	1.7	15
322	Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. <i>Clinical Sarcoma Research</i> , 2012, 2, .	2.0	26
323	Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST). <i>Current Treatment Options in Oncology</i> , 2012, 13, 277-284.	4.3	17
324	Leiomyosarcoma and sarcoma with myogenic differentiation. <i>Cancer</i> , 2012, 118, 5349-5357.	4.4	3

#	ARTICLE	IF	CITATIONS
325	Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <i>Cancer</i> , 2012, 118, 5857-5866.	4.4	83
326	Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 111-126.	3.5	22
327	Gastrointestinal Stromal Tumor of the Rectum: Results of Surgical and Multimodality Therapy in the Era of Imatinib. <i>Annals of Surgical Oncology</i> , 2012, 20, 586-592.	1.7	104
328	Prognostic determinants in epithelioid sarcoma. <i>European Journal of Cancer</i> , 2011, 47, 287-295.	3.3	45
329	Natural History of Imatinib-naïve GISTs. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1646-1656.	3.9	112
330	Surgery in Retroperitoneal Soft Tissue Sarcoma: A Call for a Consensus Between Europe and North America. <i>Annals of Surgical Oncology</i> , 2011, 18, 2107-2110.	1.7	36
331	Proteomic detection of a large amount of SCGF± in the stroma of GISTs after imatinib therapy. <i>Journal of Translational Medicine</i> , 2011, 9, .	6.5	9
332	High CD133 expression levels in gastrointestinal stromal tumors. <i>Cytometry Part B - Clinical Cytometry</i> , 2011, 80B, 238-247.	1.7	9
333	Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study. <i>International Journal of Cancer</i> , 2011, 128, 983-990.	4.5	18
334	Dermatofibrosarcoma protuberans-derived fibrosarcoma: Clinical history, biological profile and sensitivity to imatinib. <i>International Journal of Cancer</i> , 2011, 129, 1761-1772.	4.5	62
335	Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. <i>Annals of Oncology</i> , 2011, 22, 1675-1681.	1.5	40
336	Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. <i>Annals of Oncology</i> , 2011, 22, 1682-1690.	1.5	188
337	Surgical Technique, Morbidity, and Outcome of Primary Retroperitoneal Sarcoma Involving Inferior Vena Cava. <i>Annals of Surgical Oncology</i> , 2011, 19, 511-518.	1.7	98
338	The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones. <i>Annals of Surgical Oncology</i> , 2011, 19, 1051-1055.	1.7	30
339	Surgical Treatment. , 2011, , 107-112.		0
340	Aggressive fibromatosis in children and adolescents. <i>Cancer</i> , 2010, 116, 233-240.	4.4	121
341	Extremity Soft Tissue Sarcoma in a Series of Patients Treated at a Single Institution. <i>Annals of Surgery</i> , 2010, 251, 506-511.	4.9	263
342	Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma Carried Out at High-Volume Centers is Safe and is Associated With Improved Local Control. <i>Annals of Surgical Oncology</i> , 2010, 17, 1507-1514.	1.7	262

#	ARTICLE	IF	CITATIONS
343	Peritoneal Sarcomatosis: Is There a Subset of Patients Who May Benefit from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2010, 17, 3220-3228.	1.7	77
344	Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. <i>BMC Cancer</i> , 2010, 10, .	3.0	31
345	The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor. <i>Cancer</i> , 2010, 116, 1847-1858.	4.4	24
346	Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. <i>Cancer</i> , 2010, 116, 2429-2436.	4.4	89
347	Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 4958-4967.	6.4	26
348	Sunitinib Malate and Figitumumab in Solitary Fibrous Tumor: Patterns and Molecular Bases of Tumor Response. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1286-1297.	1.7	81
349	Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells. <i>Cancer Research</i> , 2010, 70, 2235-2244.	0.6	241
350	Tumor response to sunitinib malate observed in clear-cell sarcoma. <i>Annals of Oncology</i> , 2010, 21, 1130-1131.	1.5	35
351	Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?. <i>Annals of Oncology</i> , 2010, 21, 403-408.	1.5	123
352	Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. <i>Neuro-Oncology</i> , 2010, 12, 776-789.	0.9	79
353	Alveolar Soft Part Sarcoma: Clinical Presentation, Treatment, and Outcome in a Series of 33 Patients at a Single Institution. <i>Annals of Surgical Oncology</i> , 2010, 17, 3229-3233.	1.7	79
354	Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2010, 18, 720-725.	1.7	201
355	ILP and RT: The Study That Will Never Be. <i>Annals of Surgical Oncology</i> , 2010, 18, 303-305.	1.7	11
356	Hyperthermia as an adjunctive treatment for soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 199-210.	2.6	25
357	Soft Tissue Sarcomas of Childhood and Adolescence: The Prognostic Role of Tumor Size in Relation to Patient Body Size. <i>Journal of Clinical Oncology</i> , 2009, 27, 371-376.	17.1	50
358	Resection of Uninvolved Adjacent Organs Can Be Part of Surgery for Retroperitoneal Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 2106-2107.	17.1	46
359	Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. <i>Annals of Oncology</i> , 2009, 20, 1439-1444.	1.5	105
360	Response to imatinib plus sirolimus in advanced chordoma. <i>Annals of Oncology</i> , 2009, 20, 1886-1894.	1.5	137

#	ARTICLE	IF	CITATIONS
361	Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma. <i>Clinical Cancer Research</i> , 2009, 15, 1096-1104.	6.4	124
362	Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 449-457.	1.7	154
363	Activate and resist: L576P-KIT in GIST. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2491-2495.	1.7	31
364	Gastrointestinal Stromal Tumors I: Pathology, Pathobiology, Primary Therapy, and Surgical Issues. <i>Seminars in Oncology</i> , 2009, 36, 290-301.	1.9	35
365	Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment. <i>Annals of Surgical Oncology</i> , 2009, 16, 2587-2593.	1.7	318
366	Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). <i>European Journal of Cancer</i> , 2009, 45, 1103-1106.	3.3	29
367	Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). <i>European Journal of Surgical Oncology</i> , 2009, 35, 739-745.	0.9	146
368	PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. <i>Neuro-Oncology</i> , 2009, 11, 725-736.	0.9	72
369	Aggressive Surgical Policies in a Retrospectively Reviewed Single-Institution Case Series of Retroperitoneal Soft Tissue Sarcoma Patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 24-30.	17.1	406
370	Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1145-1157.	2.6	38
371	Desmoid-type fibromatosis: What works best?. <i>European Journal of Cancer</i> , 2009, 45, 466-467.	3.3	10
372	Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers. <i>Annals of Surgical Oncology</i> , 2009, 17, 211-219.	1.7	152
373	The prognostic impact of dedifferentiation in retroperitoneal liposarcoma. <i>Cancer</i> , 2008, 113, 1657-1665.	4.4	80
374	Is Autophagy Rather Than Apoptosis the Regression Driver in Imatinib-Treated Gastrointestinal Stromal Tumors?. <i>Translational Oncology</i> , 2008, 1, 177-186.	3.8	20
375	Banked venous homograft replacement of the inferior vena cava for primary leiomyosarcoma. <i>European Journal of Surgical Oncology</i> , 2008, 34, 720-724.	0.9	17
376	Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1. <i>Clinical Cancer Research</i> , 2008, 14, 4550-4555.	6.4	145
377	Combined modalities approach for localized adult extremity soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1135-1144.	2.6	9
378	c-Kit/PDGFR Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 2369-2377.	6.4	55

#	ARTICLE	IF	CITATIONS
379	Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as Potential Targets in Treating Aggressive Fibromatosis. <i>Clinical Cancer Research</i> , 2007, 13, 5034-5040.	6.4	75
380	Chordoma. <i>Current Opinion in Oncology</i> , 2007, 19, 367-370.	2.3	138
381	Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma. <i>European Journal of Cancer</i> , 2007, 43, 2691-2697.	3.3	40
382	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. <i>Lancet Oncology</i> , The, 2007, 8, 595-602.	21.9	379
383	Myxoid/round cell and pleomorphic liposarcomas. <i>Cancer</i> , 2007, 109, 2522-2531.	4.4	145
384	Extremity Soft Tissue Sarcoma: Adding to the Prognostic Meaning of Local Failure. <i>Annals of Surgical Oncology</i> , 2007, 14, 1583-1590.	1.7	71
385	Epithelioid Sarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2007, 14, 3542-3551.	1.7	78
386	Soft-tissue sarcomas of the extremities in patients of pediatric age. <i>Journal of Children's Orthopaedics</i> , 2007, 1, 195-203.	1.8	9
387	Prognostic Effect of Re-Excision in Adult Soft Tissue Sarcoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2006, 13, 110-117.	1.7	137
388	Epithelioid sarcoma in children and adolescents. <i>Cancer</i> , 2006, 106, 708-717.	4.4	96
389	Malignant peripheral nerve sheath tumors. <i>Cancer</i> , 2006, 107, 1065-1074.	4.4	349
390	Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas. <i>Clinical Cancer Research</i> , 2006, 12, 6920-6928.	6.4	128
391	Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression. <i>Cancer Research</i> , 2006, 66, 8918-8924.	0.6	112
392	Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2006, 14, 553-559.	1.7	60
393	Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. <i>Cancer</i> , 2005, 103, 402-408.	4.4	174
394	9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for kit and platelet-derived growth factor receptor \pm gene alterations. <i>Cancer</i> , 2005, 104, 159-169.	4.4	53
395	Adult-Type Soft Tissue Sarcomas in Pediatric-Age Patients: Experience at the Istituto Nazionale Tumori in Milan. <i>Journal of Clinical Oncology</i> , 2005, 23, 4021-4030.	17.1	123
396	Dermatofibrosarcoma Protuberans Treated at a Single Institution: A Surgical Disease With a High Cure Rate. <i>Journal of Clinical Oncology</i> , 2005, 23, 7669-7675.	17.1	170

#	ARTICLE	IF	CITATIONS
397	Status of Surgical Margins and Prognosis in Adult Soft Tissue Sarcomas of the Extremities: A Series of Patients Treated at a Single Institution. <i>Journal of Clinical Oncology</i> , 2005, 23, 96-104.	17.1	235
398	Consensus meeting for the management of gastrointestinal stromal tumorsâ€ Report of the GIST Consensus Conference of 20â€21 March 2004, under the auspices of ESMO. <i>Annals of Oncology</i> , 2005, 16, 566-578.	1.5	586
399	Carney triad: case report and molecular analysis of gastric tumor. <i>Human Pathology</i> , 2005, 36, 112-116.	2.4	59
400	Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor Î² Tyrosine Kinase Receptors in Synovial Sarcoma. <i>Clinical Cancer Research</i> , 2004, 10, 938-943.	6.4	57
401	Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis. <i>Cancer</i> , 2004, 100, 1943-1950.	4.4	100
402	Retroperitoneal soft tissue sarcomas. <i>Cancer</i> , 2004, 100, 2448-2455.	4.4	164
403	Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution. <i>Cancer</i> , 2004, 101, 627-634.	4.4	329
404	Imatinib mesylate in chordoma. <i>Cancer</i> , 2004, 101, 2086-2097.	4.4	233
405	Sacro-coccygeal chordoma: Diagnosis and treatment review. <i>Seminars in Colon and Rectal Surgery</i> , 2004, 15, 26-32.	0.4	0
406	A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. <i>Gastroenterology</i> , 2004, 127, 294-299.	1.0	339
407	Uterine Sarcoma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion: a Feasibility Study. <i>Journal of Chemotherapy</i> , 2004, 16, 19-22.	1.7	14
408	Rhabdomyosarcoma in adults. <i>Cancer</i> , 2003, 98, 571-580.	4.4	338
409	Chordoma: Natural History and Results in 28 Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2003, 10, 291-296.	1.7	184
410	Quality of Surgery and Outcome in Extra-Abdominal Aggressive Fibromatosis: A Series of Patients Surgically Treated at a Single Institution. <i>Journal of Clinical Oncology</i> , 2003, 21, 1390-1397.	17.1	302
411	Evidence of Neural Differentiation in a Case of Post-therapy Primitive Neuroectodermal Tumor/Ewing Sarcoma of Bone. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1161-1166.	3.9	25
412	Feasibility of Peritonectomy Associated with Intraperitoneal Hyperthermic Perfusion in Patients with Pseudomyxoma Peritonei. <i>Tumori</i> , 2002, 88, 370-375.	1.5	16
413	Lack of SYT-SSX Fusion Transcripts in Malignant Peripheral Nerve Sheath Tumors on RT-PCR Analysis of 34 Archival Cases. <i>Laboratory Investigation</i> , 2002, 82, 609-618.	3.5	35
414	Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. <i>Cancer</i> , 2001, 92, 1259-1264.	4.4	222

#	ARTICLE	IF	CITATIONS
415	Hemangiopericytoma in pediatric ages. <i>Cancer</i> , 2001, 92, 2692-2698.	4.4	48
416	Preoperative radiation therapy for patients with T2-T3 carcinoma of the middle-to-lower rectum. <i>Cancer</i> , 1999, 86, 398-404.	4.4	40
417	Surgical treatment of locally recurrent rectal carcinoma. <i>Diseases of the Colon and Rectum</i> , 1997, 40, 1421-1424.	1.8	62
418	First- and second-line systemic treatments for metastatic and locally advanced soft tissue sarcomas in adults. <i>The Cochrane Library</i> , 0, , .	2.4	1